Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 5, Pages 1957-1968Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm201041d
Keywords
-
Categories
Funding
- Irish Technological Sector Research Strand I and Strand III programmes [PT03147, CRS02-TA01]
- Dublin Institute of Technology
- FOCAS Institute, DIT
Ask authors/readers for more resources
The complexes [Cu(salH)(2)(H2O)] (1), [Cu(dipsH)(2)(H2O)] (2), {Cu(3-MeOsal)(H2O)(0.75)}(n) (3), [Cu(dipsH)(2)(BZDH)(2)] (4), [Cu(dipsH)(2)(2-MeOHBZDH)(2)]center dot EtOH (5), [Cu(sal)(phen)] (6), [Cu(dips)(phen)]center dot H2O (7), and [Cu(3-MeOsal)(phen)]center dot H2O (8) (salH(2)= salicylic acid; dipsH(2) = 3,5-diisopropylsalicylic acid; 3-MeOsalH(2) = 3-methoxysalicylic acid; BZDH = benzimidazole; 2-MeOHBZDH = 2 methanolbenzimidazole and phen =1,10-phenanthroline) were prepared and characterized. Structures of 4, 5, and 8 were determined by X-ray crystallography. Compounds 1-8 are potent superoxide dismutase mimetics, and they are inactive as inhibitors of COX-2 activity. Compounds 1, 4, and 5 exhibit moderate inhibition of COX-1. Complexes 6-8 display rapid micromolar cytotoxicity against cisplatin sensitive (breast (MCF-7), prostate (DU145), and colon (HT29)) and cisplatin resistant (ovarian (SK-OV-3)) cell lines compared to 1-5, and they exhibit potent in vitro DNA binding and cleavage capabilities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available